ClinicalTrials.gov record
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
ClinicalTrials.gov ID: NCT02296138
Public ClinicalTrials.gov record NCT02296138. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD. [DYNAGITO]
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in patients with severe to very severe COPD.
Study identification
- NCT ID
- NCT02296138
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 7,903 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 13, 2015 (Actual)
- Primary completion
- Mar 8, 2017 (Actual)
- Completion
- Mar 29, 2017 (Actual)
- Last update posted
- Jun 4, 2018
2015 – 2017
United States locations
- U.S. sites
- 117
- U.S. states
- 35
- U.S. cities
- 103
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1237.19.10039 Boehringer Ingelheim Investigational Site | Andalusia | Alabama | — | — |
| 1237.19.10009 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1237.19.10077 Boehringer Ingelheim Investigational Site | Florence | Alabama | — | — |
| 1237.19.10115 Boehringer Ingelheim Investigational Site | Jasper | Alabama | — | — |
| 1237.19.10069 Boehringer Ingelheim Investigational Site | Flagstaff | Arizona | — | — |
| 1237.19.10085 Boehringer Ingelheim Investigational Site | Peoria | Arizona | — | — |
| 1237.19.10110 Boehringer Ingelheim Investigational Site | Lincoln | California | — | — |
| 1237.19.10118 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1237.19.10074 Boehringer Ingelheim Investigational Site | Poway | California | — | — |
| 1237.19.10157 Boehringer Ingelheim Investigational Site | Lafayette | Colorado | — | — |
| 1237.19.10142 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1237.19.10133 Boehringer Ingelheim Investigational Site | Norwalk | Connecticut | — | — |
| 1237.19.10093 Boehringer Ingelheim Investigational Site | Stamford | Connecticut | — | — |
| 1237.19.10029 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1237.19.10106 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1237.19.10020 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 1237.19.10000 Boehringer Ingelheim Investigational Site | St. Petersburg | Florida | — | — |
| 1237.19.10135 Boehringer Ingelheim Investigational Site | St. Petersburg | Florida | — | — |
| 1237.19.10145 Boehringer Ingelheim Investigational Site | Tamarac | Florida | — | — |
| 1237.19.10066 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1237.19.10032 Boehringer Ingelheim Investigational Site | Winter Park | Florida | — | — |
| 1237.19.10080 Boehringer Ingelheim Investigational Site | Duluth | Georgia | — | — |
| 1237.19.10011 Boehringer Ingelheim Investigational Site | Gainesville | Georgia | — | — |
| 1237.19.10112 Boehringer Ingelheim Investigational Site | Lawrenceville | Georgia | — | — |
| 1237.19.10037 Boehringer Ingelheim Investigational Site | Eagle | Idaho | — | — |
| 1237.19.10130 Boehringer Ingelheim Investigational Site | O'Fallon | Illinois | — | — |
| 1237.19.10065 Boehringer Ingelheim Investigational Site | River Forest | Illinois | — | — |
| 1237.19.10122 Boehringer Ingelheim Investigational Site | Muncie | Indiana | — | — |
| 1237.19.10063 Boehringer Ingelheim Investigational Site | Topeka | Kansas | — | — |
| 1237.19.10048 Boehringer Ingelheim Investigational Site | Bowling Green | Kentucky | — | — |
| 1237.19.10108 Boehringer Ingelheim Investigational Site | Fort Mitchell | Kentucky | — | — |
| 1237.19.10109 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 1237.19.10095 Boehringer Ingelheim Investigational Site | Opelousas | Louisiana | — | — |
| 1237.19.10113 Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| 1237.19.10139 Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| 1237.19.10117 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 1237.19.10083 Boehringer Ingelheim Investigational Site | Columbia | Maryland | — | — |
| 1237.19.10072 Boehringer Ingelheim Investigational Site | Hollywood | Maryland | — | — |
| 1237.19.10027 Boehringer Ingelheim Investigational Site | Fall River | Massachusetts | — | — |
| 1237.19.10138 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 1237.19.10103 Boehringer Ingelheim Investigational Site | Worcester | Massachusetts | — | — |
| 1237.19.10075 Boehringer Ingelheim Investigational Site | Ann Arbor | Michigan | — | — |
| 1237.19.10034 Boehringer Ingelheim Investigational Site | Farmington Hills | Michigan | — | — |
| 1237.19.10082 Boehringer Ingelheim Investigational Site | Traverse City | Michigan | — | — |
| 1237.19.10043 Boehringer Ingelheim Investigational Site | Fridley | Minnesota | — | — |
| 1237.19.10096 Boehringer Ingelheim Investigational Site | Rochester | Minnesota | — | — |
| 1237.19.10031 Boehringer Ingelheim Investigational Site | Chesterfield | Missouri | — | — |
| 1237.19.10101 Boehringer Ingelheim Investigational Site | Saint Charles | Missouri | — | — |
| 1237.19.10051 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1237.19.10084 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1237.19.10097 Boehringer Ingelheim Investigational Site | Missoula | Montana | — | — |
| 1237.19.10060 Boehringer Ingelheim Investigational Site | Reno | Nevada | — | — |
| 1237.19.10081 Boehringer Ingelheim Investigational Site | Marlton | New Jersey | — | — |
| 1237.19.10094 Boehringer Ingelheim Investigational Site | Brooklyn | New York | — | — |
| 1237.19.10137 Boehringer Ingelheim Investigational Site | Larchmont | New York | — | — |
| 1237.19.10143 Boehringer Ingelheim Investigational Site | Syracuse | New York | — | — |
| 1237.19.10035 Boehringer Ingelheim Investigational Site | Burlington | North Carolina | — | — |
| 1237.19.10014 Boehringer Ingelheim Investigational Site | Calabash | North Carolina | — | — |
| 1237.19.10098 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 1237.19.10131 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 1237.19.10049 Boehringer Ingelheim Investigational Site | Elizabeth City | North Carolina | — | — |
| 1237.19.10154 Boehringer Ingelheim Investigational Site | Gastonia | North Carolina | — | — |
| 1237.19.10104 Boehringer Ingelheim Investigational Site | Hickory | North Carolina | — | — |
| 1237.19.10087 Boehringer Ingelheim Investigational Site | Huntersville | North Carolina | — | — |
| 1237.19.10053 Boehringer Ingelheim Investigational Site | Shelby | North Carolina | — | — |
| 1237.19.10062 Boehringer Ingelheim Investigational Site | Wilmington | North Carolina | — | — |
| 1237.19.10008 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1237.19.10042 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1237.19.10127 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 1237.19.10121 Boehringer Ingelheim Investigational Site | Dayton | Ohio | — | — |
| 1237.19.10148 Boehringer Ingelheim Investigational Site | Dayton | Ohio | — | — |
| 1237.19.10005 Boehringer Ingelheim Investigational Site | Delaware | Ohio | — | — |
| 1237.19.10147 Boehringer Ingelheim Investigational Site | Kettering | Ohio | — | — |
| 1237.19.10055 Boehringer Ingelheim Investigational Site | Toledo | Ohio | — | — |
| 1237.19.10146 Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | — | — |
| 1237.19.10021 Boehringer Ingelheim Investigational Site | Medford | Oregon | — | — |
| 1237.19.10129 Boehringer Ingelheim Investigational Site | Erie | Pennsylvania | — | — |
| 1237.19.10140 Boehringer Ingelheim Investigational Site | Oaks | Pennsylvania | — | — |
| 1237.19.10003 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1237.19.10019 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1237.19.10006 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 1237.19.10136 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 1237.19.10151 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 1237.19.10041 Boehringer Ingelheim Investigational Site | East Providence | Rhode Island | — | — |
| 1237.19.10126 Boehringer Ingelheim Investigational Site | Johnston | Rhode Island | — | — |
| 1237.19.10054 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1237.19.10086 Boehringer Ingelheim Investigational Site | Columbia | South Carolina | — | — |
| 1237.19.10058 Boehringer Ingelheim Investigational Site | Easley | South Carolina | — | — |
| 1237.19.10023 Boehringer Ingelheim Investigational Site | Gaffney | South Carolina | — | — |
| 1237.19.10030 Boehringer Ingelheim Investigational Site | Gaffney | South Carolina | — | — |
| 1237.19.10024 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1237.19.10128 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1237.19.10144 Boehringer Ingelheim Investigational Site | Mt. Pleasant | South Carolina | — | — |
| 1237.19.10071 Boehringer Ingelheim Investigational Site | Myrtle Beach | South Carolina | — | — |
| 1237.19.10099 Boehringer Ingelheim Investigational Site | Old Point Station | South Carolina | — | — |
| 1237.19.10025 Boehringer Ingelheim Investigational Site | Rock Hill | South Carolina | — | — |
| 1237.19.10033 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1237.19.10036 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1237.19.10010 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
| 1237.19.10007 Boehringer Ingelheim Investigational Site | Rapid City | South Dakota | — | — |
| 1237.19.10070 Boehringer Ingelheim Investigational Site | Boerne | Texas | — | — |
| 1237.19.10107 Boehringer Ingelheim Investigational Site | Corsicana | Texas | — | — |
| 1237.19.10153 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
| 1237.19.10047 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1237.19.10111 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 1237.19.10059 Boehringer Ingelheim Investigational Site | Kingwood | Texas | — | — |
| 1237.19.10061 Boehringer Ingelheim Investigational Site | McKinney | Texas | — | — |
| 1237.19.10050 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1237.19.10091 Boehringer Ingelheim Investigational Site | Abingdon | Virginia | — | — |
| 1237.19.10076 Boehringer Ingelheim Investigational Site | Lynchburg | Virginia | — | — |
| 1237.19.10040 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1237.19.10089 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1237.19.10123 Boehringer Ingelheim Investigational Site | Everett | Washington | — | — |
| 1237.19.10120 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 1237.19.10092 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
| 1237.19.10001 Boehringer Ingelheim Investigational Site | Morgantown | West Virginia | — | — |
| 1237.19.10016 Boehringer Ingelheim Investigational Site | West Allis | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 701 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02296138, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 4, 2018 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02296138 live on ClinicalTrials.gov.